Essay on Liraglutide: Novel Treatment of Type 2 Diabetes Mellitus

1006 Words 5 Pages
Substantial advancement has been built in recent years in the development of pharmacological treatment of type 2 diabetes. The most recent developments have been around the incretin hormones. Glucagon-like peptide 1-receptor agonists (GLP-1) have demonstrated efficacy and safety in the treatment of type 2 diabetes. Liraglutide (Victoza) is a GLP-1 receptor agonist that has demonstrated advantages in lower hemoglobin A1c in this class of medications and assisting patients in reducing weight.

Liraglutide: Novel treatment of Type 2 Diabetes Mellitus
Type 2 Diabetes is rapidly becoming the top health concerns in the United States and a major contributor to health care spending and disability. There are an estimated 22.3 million people
…show more content…
Substantial advancement has been built in recent years in the development of pharmacological treatment of type 2 diabetes. The most recent developments have been around the incretin hormones. Glucagon-like peptide 1-receptor agonists (GLP-1) have demonstrated efficacy and safety in the treatment of type 2 diabetes. Liraglutide (Victoza) is a GLP-1 receptor agonist that has demonstrated advantages in lower hemoglobin A1c in this class of medications and assisting patients in reducing weight.

Liraglutide: Novel treatment of Type 2 Diabetes Mellitus
Type 2 Diabetes is rapidly becoming the top health concerns in the United States and a major contributor to health care spending and disability. There are an estimated 22.3 million people in the United States diagnosed with diabetes, this represents 7% of our population (American Diabetes Association [ADA], 2013, p. 1038) The American Diabetes Association conducted research in 2012 on the financial impact of diabetes. The authors evaluated 5 years from 2007 through 2012 and discovered the estimated cost of diabetes in 2012 was $245 billion dollars annually as compared to the estimated cost of $174 billion in 2007 (ADA, 2013, p. 1033). These figures are inclusive of care and lost productivity as well as adjusted to inflation. This represents a 41% increase in burden that patients with diabetes and healthcare consumers incur annually (ADA, 2013, p. 1033).

A rise in the amount of expenditures is expected with the
Open Document